Friday, 16 Feb 2018

You are here

DMARDs Lower Dementia Risk in Rheumatoid Arthritis

UK researchers have analyzed rheumatoid arthritis (RA) patients from the UK Clinical Practice Research Database and shown that chronic conventional DMARD (cDMARD) use was associated with 40% lower risk of dementia (nearly 50% with methotrexate use).

They compared 3876 cDMARD users to 1938 nonusers among incident RA and found a reduced risk of dementia (hazard ratio: 0.60; 95% confidence interval: 0.42-0.85). The effect was strongest in methotrexate users (hazard ratio: 0.52; 95% confidence interval; 0.34-0.82).

These results suggest a new potential therapeutic role for DMARDs and the possible contribution of inflammation on dementia.

 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

NHANES Survey Shows OA Rising and RA Declining

An analysis of 43,706 adults from the 1999-2014 National Health and Nutrition Examination Surveys (NHANES) demonstrated temporal trends in the prevalence of arthritis, including a rise in osteoarthritis (OA) from 6.6% to 14.3%, while the prevalence of rheumatoid arthritis (RA) decreased from 5.9% to 3.8% in the USA, (Citation source https://buff.ly/2o6fhkW

Abatacept Shows Promise for RA-ILD

Abatacept (Orencia) may be a useful treatment option for patients with rheumatoid arthritis (RA) who develop interstitial lung disease (ILD), a Spanish study suggested.

Weight Loss Linked to RA Improvement

By retrospectively reviewing electronic health record (EHR) data, Kreps et al found that rheumatoid arthritis (RA) patients who lost >5 kg of weight were three times more likely to demonstrate improvement in disease activity.

Researchers investigated the association between weight loss and CDAI change among patients who were overweight/obese at baseline and who lost weight during follow-up.

IL-1 and IL-6 Inhibition Preferred in Systemic JIA

Since 2000, the German Biologics register (BiKeR) has prospectively enrolled children with juvenile idiopathic arthritis to assess outcomes with biologic therapies.  A new report evaluates the efficacy and safety of etanercept (ETA), tocilizumab (TOC) and the interleukin-1 inhibitors (anakinra and canakinumab) (IL-1i) in those with systemic onset juvenile idiopathic arthritis JIA (sJIA).

Increasing Adverse Events Seen with Higher Disease Activity in Early RA

Researchers in the NEO-RACo Study Group studied adverse events (AEs) in relation to disease activity in patients with early rheumatoid arthritis (RA).